gepotidacin
Small moleculeapproved
Approved
Mar 25, 2025
Gepotidacin, sold under the brand name Blujepa, is an antibiotic medication used for the treatment of urinary tract infection. Gepotidacin is a triazaacenaphthylene bacterial type II topoisomerase inhibitor. It is used as the salt gepotidacin mesylate, and is taken by mouth. — Wikipedia
Clinical trial activity
22 trials · 4 clinical orgs · 1 marketing orgs
Phase 1
14
Phase 2
8
Phase 3
5
Phase 4
0
Earliest trial started Sep 26, 2011 (NCT02202187)
Timeline
2010s
- Jan 1, 2011
GlaxoSmithKline — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2014
GlaxoSmithKline — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2019
GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)
2020s
- Mar 25, 2025
Earliest FDA Approval
- Mar 25, 2025
GlaxoSmithKline — Marketing Organization
Indications
Approved for
Mechanism of action
Top1B inhibitor
- Topoisomerase IVINHIBITOR
Topoisomerase IV inhibitor
- Bacterial DNA gyraseINHIBITOR
Bacterial DNA gyrase inhibitor
Approval history
- approvedPriority reviewMar 25, 2025
Chemistry & pharmacology
Loading structure…
SMILES
O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1- Mol. weight
- 448.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGepotidacin ↗
- ChEMBLCHEMBL3317856 ↗
Also known as
- gepotidacin
- gepotidacin
- gepotidacin
- gepotidacin
- gepotidacin
- gsk2140944
- gsk2140944
- gsk2140944
- gsk2140944
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06597344 | Phase 3 | Oct 2, 2024 | GlaxoSmithKline |
| NCT05630833 | Phase 3 | Dec 12, 2022 | GlaxoSmithKline |
| NCT05271799 | Phase 1 | Mar 1, 2022 | GlaxoSmithKline |
| NCT04484740 | Phase 1 | Sep 1, 2020 | Institut National de la Santé Et de la Recherche Médicale, France, Medical University of Vienna |
| NCT04493931 | Phase 1 | Aug 14, 2020 | GlaxoSmithKline |
| NCT04187144 | Phase 3 | Mar 20, 2020 | GlaxoSmithKline |
| NCT04010539 | Phase 3 | Sep 20, 2019 | GlaxoSmithKline |
| NCT04020341 | Phase 3 | Sep 20, 2019 | GlaxoSmithKline |
| NCT04079790 | Phase 1 | Aug 9, 2019 | GlaxoSmithKline |
| NCT03568942 | Phase 2 | Jul 23, 2018 | Department of Health and Human Services, GlaxoSmithKline |
| NCT03562117 | Phase 1 | Jun 11, 2018 | Department of Health and Human Services, GlaxoSmithKline |
| NCT02853435 | Phase 1 | Aug 4, 2016 | GlaxoSmithKline |
| NCT02729038 | Phase 1 | Jun 29, 2016 | GlaxoSmithKline |
| NCT02294682 | Phase 2 | Apr 15, 2015 | GlaxoSmithKline |
| NCT02257398 | Phase 1 | Oct 6, 2014 | GlaxoSmithKline |
| NCT02045797 | Phase 2 | Mar 1, 2014 | GlaxoSmithKline |
| NCT02045849 | Phase 1 | Jan 28, 2014 | GlaxoSmithKline |
| NCT02000765 | Phase 1 | Nov 8, 2013 | GlaxoSmithKline |
| NCT01934205 | Phase 1 | Sep 25, 2013 | GlaxoSmithKline |
| NCT01706315 | Phase 1 | Oct 17, 2012 | GlaxoSmithKline |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 21 | 21 | 3 | 2011 |
| Department of Health and Human Services | Government | 2 | 0 | 2 | 2018 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Medical University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | MKTG | Mar 25, 2025 |